azd5305
Small moleculeexperimental
Clinical trial activity
13 trials · 9 clinical orgs · 0 marketing orgs
Phase 1
8
Phase 2
8
Phase 3
3
Phase 4
0
Earliest trial started Nov 12, 2020 (NCT04644068)
Timeline
Indications
Studied for
- Adenocarcinoma of Lung · Phase 1/Phase 2
- Biliary Tract Neoplasms · Phase 2
- Breast Neoplasms · Phase 3
- Carcinoma, Non-Small-Cell Lung · Phase 1
- Carcinoma, Transitional Cell · Phase 2
- Colorectal Neoplasms · Phase 2
- Endometrial Neoplasms · Phase 2
- Neoplasms · Phase 1
- Ovarian Neoplasms · Phase 2
- Pancreatic Neoplasms · Phase 1
- Prostatic Neoplasms · Phase 3
- Prostatic Neoplasms, Castration-Resistant · Phase 3
- Small Cell Lung Carcinoma · Phase 2
- Stomach Neoplasms · Phase 2
- Urinary Bladder Neoplasms · Phase 1
- Uterine Cervical Neoplasms · Phase 1
Mechanism of action
- Poly [ADP-ribose] polymerase 10INHIBITOR
PARP10 inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
CCc1cc2ncc(CN3CCN(c4ccc(C(=O)NC)nc4)CC3)cc2[nH]c1=O- Mol. weight
- 406.49 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL5095220 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06769126 | Phase 2 | Dec 1, 2025 | National Cancer Institute (NCI), SWOG Cancer Research Network |
| NCT07060365 | Phase 1/Phase 2 (Phase 2) | Sep 2, 2025 | AstraZeneca, Parexel |
| NCT06952803 | Phase 3 | Aug 6, 2025 | AstraZeneca, Parexel |
| NCT06899061 | Phase 1 | Mar 25, 2025 | AstraZeneca, Parexel |
| NCT06713369 | Phase 1 | Dec 18, 2024 | AstraZeneca, Fortrea |
| NCT06380751 | Phase 3 | Aug 1, 2024 | AstraZeneca |
| NCT06120491 | Phase 3 | Nov 21, 2023 | AstraZeneca, Peter MacCallum Cancer Centre |
| NCT05938270 | Phase 1 | Sep 21, 2023 | AstraZeneca |
| NCT05797168 | Phase 1/Phase 2 (Phase 2) | Jun 5, 2023 | AstraZeneca, University of Texas at Houston |
| NCT05573724 | Phase 1 | Nov 7, 2022 | AstraZeneca |
| NCT05489211 | Phase 2 | Sep 6, 2022 | AstraZeneca, Daiichi Sankyo |
| NCT05367440 | Phase 1/Phase 2 (Phase 2) | Jun 2, 2022 | AstraZeneca, Bayer |
| NCT04644068 | Phase 1 | Nov 12, 2020 | AstraZeneca, University of Texas at Houston |
Showing 13 of 13 trials
Page 1 / 1
Organizations
Research & Development (9)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| AstraZeneca | For profit | 12 | 12 | 3 | 2020 |
| Parexel | For profit | 3 | 0 | 3 | 2025 |
| University of Texas at Houston | Academic/Hospital | 2 | 0 | 2 | 2020 |
| Bayer | For profit | 1 | 0 | 1 | 2022 |
| Daiichi Sankyo | For profit | 1 | 0 | 1 | 2022 |
| Fortrea | For profit | 1 | 0 | 1 | 2024 |
| National Cancer Institute (NCI) | Government | 1 | 0 | 1 | 2025 |
| Peter MacCallum Cancer Centre | Academic/Hospital | 1 | 0 | 1 | 2023 |
| SWOG Cancer Research Network | Academic/Hospital | 1 | 1 | 1 | 2025 |
9 organizations
Page 1 / 1